Great company. Pharma, medical devices and consumer are their 3 divisions, which makes them unique--that diversification serves them well, unlike phrama companies depend solely on their pharma division. Has raised dividend for 54 years. Well run. 

He loves it.  The judgment against them is not significant.  He has a model price of $160.81, a 20% upside.  It is in the top 100 of the S&P 500 - it is US and priced in US Dollars – all the things he loves.

Their stock has done nothing this year, partially because of pricing pressure from Donald Trump. She thinks their pharma division is doing well, with lots of new products and a good pipeline. They have identified 10 drugs that have a $1 billion potential. This company spends 13% of revenues on R&D, which shows a serious level of investment in the future. They have also made some acquisitions to go into new areas. They have increased their dividend consistently for over 50 years. (Analysts’ price target is $143.29)

(Past Top Pick on May 16, 2017, Down 1.5%)  Their pharma side and newly released drugs are doing very well which offsets their drugs that are going generic. They have a solid pipeline of 10 new drugs over the next few years, each drug expected to make $1-billion. They invest in R&D and buy companies occasionally, including one last year.  Yield under 3%.

(A Past Top Pick on May 16, 2017, Up 6%) Expects tomorrow's Q1 report to be good. They're seeing good growth in their pharmaceutical division. They invest in their pipeline, so there's organic growth; They also make strategic acquisitions, like a Swiss biotech last year that focuses on heart diseases. In the pharma side, their investments are starting to pay off and offsetting some of their drugs going generic. A defensive play with strong financials.

(A Top Pick February 17, 2017. Up 11.49%). Still likes it and added to her portfolio as it pulled back last week. Their pharma business is doing quite well. This is their highest-margin business. They invest about 13% of revenues into R&D, which supports a strong pipeline. They will use some of their strong cash flow to pay down debt. Their dividend, 2%, has grown every year for 55 years.

Has dropped, along with everything else. You have to consider whether it is cheap at this level. If you look beyond the past few days, you will see that at the beginning of 2017, it was trading at about $100 per share. Now it is over $128, so today’s price is significantly increased over a short time. The business trades at a low multiple at this level (15 to 16 times earnings), near “cheap” levels. JNJ is made up of three businesses: pharma, consumer products and medical devices. The company might be more interesting if it split these into separate businesses. He doesn’t think investors will go wrong by holding this company as is, but this is not a pound-the-table opportunity at this price.

She likes this, because their pharmacy division is doing very well in terms of product pipeline development and new products they’ve launched in the last 2 years. Their Pharma division is the most profitable and very beneficial to the bottom line. This will be benefiting from the US tax cuts. An attractive yield of 2.4%.

(A Top Pick Dec 14/16. Up 28%.) She continues to like this. All 3 divisions are doing well, but their pharmaceutical division is doing particularly well.

The US$ has weakened against all currencies this year, and for US multinationals that is going to be a nice tailwind for them. About 50% of revenues come from North America. About 45% of revenues come from the pharmaceutical division, and then they have the medical devices and the consumer products division. Their Pharma division has really started to show nice organic growth, and investments in their pipeline are paying off. Going forward, management has indicated they expect to file 10 new products by 2019 with revenue potential of $1 billion, so she sees good visibility in the pipeline going forward. Organic growth is picking up. They increase the dividend every year and have done so for the last 55 years. Dividend yield of 2.5%. (Analysts’ price target is $142.)

He is going to continue to hold this because the long term potential is fantastic.  Remicade came off patent this year and had a slippage this year more than the street expected.  You have your JNJ baby labels, shampoo and big pharma and then all of your medical devices.  They are quite diversified.  You need to see some backfill on the bottom line really justify the next leg up.